A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

Inclusion Criteria:

• Male and female subjects, aged 18 to 65 years, inclusive

• Body mass index between 17 and 28 kg/m2 , inclusive

• LDL-C normal or elevated at screening and baseline.

• Willing to comply with protocol required visit schedule and visit requirements andprovide written informed consent.

• The clinical laboratory examination of the subjects was within the normal range, orabnormal but had no clinical significance as judged by the investigators, and didnot affect the study results;

• Vital signs, physical examination, ECG, ultrasound showed normal or abnormal but noclinically significant as determined by the investigator.

Exclusion Criteria:

• With a clear history of primary diseases of major organs, the subject is notsuitable to participate in this study considered by the investigator;

• Diagnosis of diabetes mellitus;

• Pregnant or breastfeeding women;

• Any conditions which, in the opinion of the Investigator, would make the subjectunsuitable for enrollment or could interfere with the subject's participation in orcompletion of the study.